PD-L1 on Circulating Tumor Cells Indicates Poor Prognosis in Breast Cancer

PD-L1 on Circulating Tumor Cells Indicates Poor Prognosis in Breast Cancer

Background: In breast cancer, research concerning programmed death-ligand 1 (PD-L1) on circulating tumor cells (CTCs) is limited. Besides, the best cell type for determining the prognostic and predictive values of PD-L1 has not been established. This study investigated associations between PD-L1 on...

Full description

Bibliographic Details
Main Authors:	Xue-fei Wang, Guo-chao Zhang, Sha-fei Wu, Jia-xin Li, Qiang Sun
Format:	Article
Language:	English
Published:	IMR Press 2022-11-01
Series:	Clinical and Experimental Obstetrics & Gynecology
Subjects:	breast cancer programmed-cell death ligand-1 (pd-l1) overall survival circulating tumor cell
Online Access:	https://www.imrpress.com/journal/CEOG/49/11/10.31083/j.ceog4911249

Similar Items

Efficacy of Anti-PD-1/PD-L1 Monotherapy or Combinational Therapy in Patients Aged 75 Years or Older: A Study-Level Meta-Analysis
by: Run-Cong Nie, et al.
Published: (2021-03-01)

Prognostic significance of programmed cell death‐ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta‐analysis
by: Yushu Ouyang, et al.
Published: (2021-10-01)

PD-1 and PD-L1 Expression in Indian Women with Breast Cancer
by: Kishan R. Bharadwa, et al.
Published: (2022-01-01)

High Expression of PD-L1 Is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition
by: Nishant Thakur, et al.
Published: (2021-03-01)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
by: Wei Shi, et al.
Published: (2023-05-01)

Progress of research on PD-1/PD-L1 in leukemia
by: Huizhen Cao, et al.
Published: (2023-09-01)

Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
by: Chunyan Yue, et al.
Published: (2018-07-01)

PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy
by: Li Chen, et al.
Published: (2022-05-01)

Expression of PD-1 and PD-L1 in Breast Carcinoma: Research Protocol for a Cohort Study
by: Shreya Ghosh, et al.
Published: (2023-11-01)

Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer
by: Katsuhiro Yoshikawa, et al.
Published: (2021-03-01)

Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters
by: Anoushika Mehan, et al.
Published: (2022-03-01)

Sarcoma – correlation between CD73 and PD-L1 and their relationship with prognosis
by: Abdullah Evren Yetişir, et al.
Published: (2023-03-01)

PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics
by: Margarita Udall, et al.
Published: (2018-02-01)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
by: Melanie Janning, et al.
Published: (2019-06-01)

Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients
by: Pawłowska A, et al.
Published: (2020-10-01)

PD-1 and PD-L1 expression in rare lung tumors
by: Marton Gyulai, et al.
Published: (2023-05-01)

PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma
by: Ke Su, et al.
Published: (2022-08-01)

Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients
by: Feng Wang, et al.
Published: (2020-06-01)

Increased PD-1+Foxp3+ γδ T cells associate with poor overall survival for patients with acute myeloid leukemia
by: Jiamian Zheng, et al.
Published: (2022-12-01)

Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment
by: Suxia Geng, et al.
Published: (2022-08-01)

Increased expression of PD-L1 in endometrial cancer stem-like cells is regulated by hypoxia
by: Shasha Yin, et al.
Published: (2022-01-01)

Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer
by: Magdalena Bojko, et al.
Published: (2024-04-01)

PROTECTION OF T-LYMPHOCYTES VIA PD-1 RECEPTOR: NEW MOLECULAR MECHANISM OF CANCER IMMUNOTHERAPY
by: Sandor Szabo
Published: (2019-12-01)

Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy
by: Mohammadsaleh Jahangir, et al.
Published: (2022-12-01)

Differential Characteristics and Prognosis of PD-L1–Positive Endometrial Carcinomas: A Retrospective Chart Review
by: Justin Z. Amarin, et al.
Published: (2021-10-01)

Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer
by: Marra Jai Aghajani, et al.
Published: (2019-07-01)

Prognostic Function of Programmed Cell Death-Ligand 1 in Esophageal Squamous Cell Carcinoma Patients Without Preoperative Therapy: A Systematic Review and Meta-Analysis
by: Hongxia Cui, et al.
Published: (2021-08-01)

Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids
by: Mingbiao LI, et al.
Published: (2016-12-01)

Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer
by: Andrzej Kowalski, et al.
Published: (2021-07-01)

High serum PD‐L1 level is a poor prognostic biomarker in surgically treated esophageal cancer
by: Masaaki Ito, et al.
Published: (2020-02-01)

Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials
by: Shan Li, et al.
Published: (2020-01-01)

Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer
by: Qianqian Ren, et al.
Published: (2020-03-01)

Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancer
by: Qing Zhou, et al.
Published: (2023-02-01)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
by: Fenglong Bie, et al.
Published: (2022-02-01)

Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal
by: Zhenqing Wang, et al.
Published: (2021-08-01)

PD-L2 based immune signature confers poor prognosis in HNSCC
by: Yu Qiao, et al.
Published: (2021-01-01)

Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis
by: Fabio Scirocchi, et al.
Published: (2022-11-01)

Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade
by: Oliver Kepp, et al.
Published: (2019-10-01)

Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis
by: Mohammad Reza Javan, et al.
Published: (2016-08-01)

A real-world comparison of circulating tumor cells in breast cancer from China: Novel device, CTC counts and its overall survival
by: Feng Li, et al.
Published: (2024-04-01)